Patients with ovarian cancer are prone to peritoneal metastasis, so many patients develop ascites during the discovery of the disease or its progression. A large amount of ascites is a common concurrent symptom in patients with ovarian cancer. For patients with significant ascites like this, hyperthermic intraperitoneal chemotherapy (HIPEC) can be performed, which involves infusing chemotherapy drugs into the abdominal cavity and then combining it with thermotherapy. This treatment generally has a decent effect, especially in controlling the spread of cancer cells in the peritoneum and managing ascites.